Eric Venker Sells 200,000 Shares of Roivant Sciences Ltd.
Eric Venker, President & Immunovant CEO, sold shares worth $6.63 million.
Key Points
- Eric Venker, President & Immunovant CEO, sold 200,000 shares of Roivant Sciences Ltd. (ROIV) for $6.63 million on June 24, 2026.
- Roivant Sciences Ltd., a biopharmaceutical company, has a market cap of $24.47 billion and trades near its 52-week high of $34.68.
- Analysts maintain a strong buy consensus with a target mean price of $39.04, as institutional investors adjust their holdings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Eric Venker, who serves as the President and CEO of Immunovant, a subsidiary of Roivant Sciences Ltd., sold 200,000 shares of the company on June 24, 2026. The shares were sold at an average price of $33.16, totaling approximately $6.63 million. This transaction was conducted under a prearranged trading plan, known as Rule 10b5-1.
Insider Buying and Selling at Roivant Sciences Ltd.
In addition to Eric Venker's recent sale, there were other insider transactions reported. Jennifer Humes, the Chief Accounting Officer, sold 3,582 shares at $31.43 on June 20, 2026, and Richard Pulik, CFO, also sold 2,129 shares at the same price on the same day. These sales were not part of a prearranged plan.
Other Institutional Activity in Roivant Sciences Ltd.
Several institutional investors have been active in adjusting their positions in Roivant Sciences Ltd. FMR LLC increased its holdings by 12,201,789 shares for a total of 77,981,253 shares, valued at about $2.16 billion, marking an 18.5% increase. Morgan Stanley, however, reduced its stake by 6,531,228 shares, leaving it with 51,828,325 shares worth approximately $1.44 billion, an 11.2% decrease. BlackRock, Inc. added 3,083,785 shares, bringing its total to 44,254,260 shares valued at $1.23 billion, a 7.5% increase. UBS Group AG also increased its stake by 4,228,680 shares to 22,619,472 shares, valued at $626.6 million, a 23% increase. Meanwhile, Vanguard Capital Management LLC opened a new position with 20,680,572 shares valued at $572.9 million.
Roivant Sciences Ltd. Stock Down 1.8%
Shares of NasdaqGS:ROIV traded near $34.02 on Saturday. Roivant Sciences Ltd. has a market cap of approximately $24.47 billion. The company is not currently profitable, which is reflected in its negative forward P/E ratio of -21.82. The stock's beta is 1.137, indicating moderate volatility. It has a 52-week low of $10.71 and a high of $34.68, with a 50-day moving average of $29.46 and a 200-day moving average of $23.96.
$ROIV stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 26, 2026, Guggenheim maintained its buy rating for Roivant Sciences Ltd. with a price target of $36. Citigroup and TD Cowen also maintained their buy ratings on May 21, with targets of $42 and $41, respectively. The consensus among analysts is a strong buy, with a mean target price of $39.04 based on 12 opinions.
About Roivant Sciences Ltd.
Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company based in London, United Kingdom. Founded in 2014, the company focuses on discovering, developing, and commercializing innovative medicines and technologies. Its product pipeline includes candidates targeting autoimmune and cardiopulmonary diseases, as well as various immune-mediated conditions. Roivant employs approximately 721 individuals and is led by CEO Matthew Gline.
Bottom Line
Eric Venker's planned sale of shares in Roivant Sciences Ltd. is a notable insider transaction, reflecting ongoing activity in the company's stock. Roivant continues to attract attention with a strong buy consensus from analysts, despite its current lack of profitability. Investors keep a close eye on such developments, as insider and institutional actions can provide insights into the company's potential direction.
Get Roivant Sciences Ltd. alerts
New 13F filings, insider trades, and analyst moves on $ROIV, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.